Loading clinical trials...
Loading clinical trials...
A Phase 2, Multicenter, Single Arm, Open Label Study of Venetoclax Plus Lenalidomide and Dexamethasone for the Treatment of Newly Diagnosed t(11;14)-Positive Multiple Myeloma in Subjects Who Are Ineligible for High-Dose Therapy
Conditions
Interventions
venetoclax
lenalidomide
+1 more
Locations
22
United States
City of Hope /ID# 212211
Duarte, California, United States
Marin Cancer Care /ID# 208476
Greenbrae, California, United States
University of California, Los Angeles /ID# 208516
Los Angeles, California, United States
Karmanos Cancer Institute /ID# 208805
Detroit, Michigan, United States
Henry Ford Hospital /ID# 208481
Detroit, Michigan, United States
Duke University Hospital /ID# 208306
Durham, North Carolina, United States
Start Date
April 29, 2019
Primary Completion Date
August 22, 2019
Completion Date
August 22, 2019
Last Updated
August 28, 2019
NCT06152575
NCT06179888
NCT04973605
NCT05201781
NCT05862012
NCT06138275
Lead Sponsor
AbbVie
Collaborators
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions